Medical Devices

Backed by FDA approval and strong clinical data, EBR Systems' leadless WiSE pacer is set to transform cardiac therapy for previously untreatable patients.

A 26-spot jump in U.S. News rankings reveals how Auburn's targeted investments in new programs and facilities are paying off for students and the state.

Highridge Medical's new deal for the Waypoint GPS brings a radiation-free, cost-effective navigation tool to spine surgery, challenging complex robotics.

With late-stage trials for two common eye conditions affecting millions, Cloudbreak Pharma is advancing novel drops where no approved drugs exist.

Positive Phase 1b data for two novel drugs suggests a long-acting, once-monthly oral therapy for recurrent genital herpes may be on the horizon.

Behavior Labs launches a new platform to close the life sciences' 'ground truth gap,' replacing slow quarterly reviews with continuous, daily intelligence.

Vafa Jamali, known for a $1.75B exit, joins CIRCA's board, signaling a major growth push beyond monitoring into advanced cardiac access technologies.

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

A Sarasota innovator challenges orthopedic giants with a resorbable device that works with the body, promising faster, better patient recovery.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

AllRock Bio has begun a Phase 2a trial for its novel drug ROC-101, testing it in combination with new standard-of-care therapies for pulmonary hypertension.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

A new paper warns that Lyme disease may pass from mother to child, a risk overlooked for decades. Researchers are now demanding urgent action and funding.

Aptar Digital Health and Enable Injections are pairing the enFuse® wearable injector with a new digital app to transform self-care for chronic diseases.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.